TIKI100

Company Overview

Snapshot

Founded in July 2023, TIKI100 operates with 1–10 employees and has raised $1.15 million across one funding round from Israel Innovation Authority. In March 2026, the company secured a grant from the Israel Innovation Authority.

Business overview

TIKI100 is developing a catheter-based medical device for women experiencing chronic urinary incontinence due to neurogenic and non-neurogenic voiding dysfunction. The company's core technology involves a urethral insert designed to restore urinary control and continuously monitor health indicators such as body temperature, pH, glucose, and signs of infection. TIKI100 serves the Health Tech & Life Sciences sector, specifically targeting female patients seeking advanced solutions for urinary control, health monitoring, and improved communication with healthcare providers.

Strategic signal

TIKI100's grant from the Israel Innovation Authority in March 2026 highlights a significant validation of its innovative medical device. This funding signals strong governmental support for the company's R&D efforts in developing a smart urinary catheter, indicating potential for accelerated product development and market entry within the Health Tech & Life Sciences sector.

Company Intelligence Q&A

What is TIKI100's primary focus?

TIKI100 is focused on developing a catheter-based medical device for women with chronic urinary incontinence, aiming to provide urinary control and monitor health indicators.

When was TIKI100 founded?

TIKI100 was founded in July 2023.

What was a key funding event for TIKI100?

In March 2026, TIKI100 secured a grant from the Israel Innovation Authority, which contributed to its total funding of $1.15 million.

What is the current employee size of TIKI100?

TIKI100 currently has 1–10 employees.

What is the product stage of TIKI100's medical device?

TIKI100's medical device is currently in the R&D product stage. The company received a grant from the Israel Innovation Authority in March 2026 to support its development.